Meeting
2019 Genitourinary Cancers Symposium
Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.
Authors
Pavlos Msaouel
University of Texas MD Anderson Cancer Center, Houston, TX
Pavlos Msaouel , Rebecca Slack-Tidwell , Giannicola Genovese , Najat C. Daw , Arlene O. Siefker-Radtke , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03587662
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS678)
DOI
10.1200/JCO.2019.37.7_suppl.TPS678
Abstract #
TPS678
Poster Bd #
K9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).
First Author: Scott T. Tagawa
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH).
First Author: Choong-kun Lee
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2019 Genitourinary Cancers Symposium
Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies.
First Author: Pavlos Msaouel